Safety-first research digest
Ipamorelin is the cleanest of the growth hormone peptides on paper — and the one with the least long-term human safety data behind it.
A bright, plain-English read on what people report, what the studies actually measured, and exactly where the evidence runs out. Every number is cited.
Start here
Here's the honest one-liner: ipamorelin is a small lab-made peptide (a peptide is just a short chain of amino acids, the building blocks of protein) that nudges your body to release a pulse of its own growth hormone — and it does that without raising the stress hormones that messier older peptides raised. That clean profile is the headline. The catch is the other half of the story: almost nobody has studied ipamorelin in people for long enough to know what happens over months or years.
In its founding study it released growth hormone strongly but left cortisol and prolactin alone [1]. Its one real human trial — for sluggish bowels after surgery — didn't work and was dropped [3]. People who use it research-style report better sleep and faster recovery, but also flushing, puffiness, and hunger after injecting — and what people report, including the downsides, is laid out plainly on the effects page. Ipamorelin is not FDA-approved, and despite the word in this site's name, it is not a prescription drug you can actually be scripted. This is an editorial digest of the research — nothing here is sold, dosed, or prescribed.
Why "selective" is the whole story
Ipamorelin's reputation rests on one finding. In its 1998 founding characterization it released growth hormone (GH) potently in rat pituitary cells, anaesthetised rats, and conscious pigs — in pigs its half-maximal dose was 2.3 nmol/kg, roughly on par with the older peptide GHRP-6 — yet it did not raise ACTH or cortisol above baseline even at doses more than 200 times its GH threshold [1]. That made it the first highly GH-selective growth hormone secretagogue (a secretagogue is simply a substance that tells a gland to secrete a hormone).
What that buys you, on the safety side, is the absence of two problems that dog the older peptides GHRP-6 and GHRP-2: a spike in the stress hormone cortisol, and a rise in prolactin [1]. Ipamorelin sidesteps both. That is a genuine, mechanism-based advantage — and it is the single best reason the safety conversation around this peptide is calmer than it is for its predecessors.
What the safety record actually contains
Strip away the marketing and the safety record is short. The only controlled human study of any size is a 2014 Phase 2 trial in 114 adults having bowel surgery, given ipamorelin intravenously twice a day for up to seven days [3]. Treatment-emergent adverse events occurred in 87.5% of the ipamorelin group versus 94.8% of the placebo group — so no ipamorelin-specific safety alarm went off in that short window [3]. But the trial missed its goal (median time to first tolerated meal was 25.3 hours on ipamorelin versus 32.6 hours on placebo, p=0.15), and development stopped [3].
The one clean instrument reading we have in people is pharmacokinetic: a terminal half-life of about 2 hours, with the GH pulse peaking around 40 minutes after dosing [2]. Beyond those two studies, human safety data is essentially absent. There is no Phase 3 trial, no long-term database, and no published safety characterization of the subcutaneous self-injection route most research-use protocols actually use [2][3]. You can read the full Ipamorelin research for the study-by-study picture.
The signals worth taking seriously
Two cautions stand out, and both are class-level rather than ipamorelin-specific. First, a 28-day study of a different drug in the same ghrelin-receptor family found dose-dependent heart-muscle degeneration in rats [6]. Ipamorelin itself was never tested that way over that long, so the honest reading is: chronic systemic dosing of this receptor class deserves scrutiny, and ipamorelin has not earned a clean bill on that front [6].
Second, growth hormone tells the liver to make IGF-1, a growth signal that pushes cells to divide [1]. That raises a theoretical concern about anything that grows — there is no ipamorelin cancer study in humans either way [3]. These aren't reasons to panic; they're reasons the Ipamorelin effects page exists, where the cautions are laid out with their mechanisms and citations. Want the short reads? Check whether does ipamorelin cause water retention and how long does ipamorelin stay in your system.